Rocket VR Health Enters Newchip Accelerator

Rocket VR Health announced its participation in Newchip’s global accelerator programme designed to fund, build, and scale startups and companies.

The Newchip Seed Accelerator provides Rocket VR Health with industry experts, mentors, and advisors that personally assist with the immersive firm’s global growth, Nik Vassev, COO and Co-Founder of Rocket VR Health, explained in a statement

He added,

“This partnership will allow us to continue developing innovative tools for patients at every step of their cancer journey”

Newchip’s digital accelerator scheme targets more than 1,500 founders and firms, and the company will provide roughly $450 million USD in funding to build a portfolio worth roughly $9 billion.

Newchip’s seed funding will help the healthcare firm generate traction and revenue. Armando Vera Carvajal, the Vice President of Product at Newchip added,

“Innovative healthcare technology companies like Rocket VR Health can scale quickly with proper funding and guidance. We are excited for Rocket VR Health and believe they will be well positioned to take advantage of our fast-expanding global ecosystem at Newchip”

Immersive, Engaging Healthcare

Rocket VR Health is developing an immersive healthcare solution which distributes digital therapeutic courses to cancer patients and survivors.

The Rocket VR Health product utilises Pico Interactive headsets from parent company ByteDance to provide patients with rich therapeutic services.

It was great to join all the leading #VR innovators and community at our very first conference #AWE2022 pic.twitter.com/KZbe9OA4UK

— Rocket VR Health (@RocketVRHealth) June 4, 2022

Rocket VR Health’s immersive therapy lasts four weeks and it supplies patients undergoing transplant therapy and social isolation with engaging immersive activities to assist with recovery periods.

The service also incorporates outdoor-styled VR environments where patients can enjoy digital activities such as gaming, wellness, and on-demand therapy.

The news comes after the Massachusetts General Hospital partnered with Rocket VR Health in March to co-develop clinical therapies for cancer patients.

The partnership also supports the development of immersive solutions for patients undergoing hematopoietic stem cell transplantation (HCT) treatments.

HCT patients often become bedridden, and Rocket VR Health’s product aims to improve the quality of life for these individuals undergoing HCT treatments at the Massachusetts location.